Eyebright Medical(688050) Sou Hu Cai Jing·2025-05-31 00:40Core Viewpoint - Aibo Medical (688050) has announced its 2024 annual profit distribution plan, proposing a cash dividend of 3.50 yuan per 10 shares, which will be subject to shareholder approval [2][3][11]. Group 1: Stock Performance - As of May 30, 2025, Aibo Medical's stock closed at 71.41 yuan, down 4.9% from the previous week [1]. - The stock reached a weekly high of 75.09 yuan on May 26 and a low of 71.21 yuan on May 28 [1]. - The company's current total market capitalization is 13.792 billion yuan, ranking 18th out of 126 in the medical device sector and 1112th out of 5146 in the A-share market [1]. Group 2: Profit Distribution Plan - Aibo Medical plans to distribute a total cash dividend of 67,548,370.05 yuan (including tax) based on a total share capital of 193,138,143 shares, excluding 142,800 shares held in the repurchase account [2]. - The total cash dividend and share repurchase amount to 87,591,975.59 yuan, representing 22.55% of the net profit attributable to shareholders for 2024 [2]. Group 3: Board and Management Decisions - The second board meeting approved the nomination of candidates for the third board of directors, including both non-independent and independent directors, pending shareholder approval [3]. - The board also approved the use of 40,556,134.86 yuan of raised funds to replace pre-invested project funds and expenses [3]. - Aibo Medical will provide a loan of up to 260 million yuan to its subsidiary, Jiangsu Tianyan Pharmaceutical Technology Co., Ltd., for project implementation [6]. Group 4: Shareholder Meeting - Aibo Medical will hold its 2024 annual shareholder meeting on June 19, 2025, to review multiple proposals and elect members of the third board of directors [5][11]. Group 5: Stock Incentive Plan - The board approved the conditions for the fourth vesting period of the initial stock incentive plan, allowing 239,112 shares to vest for 71 participants, and 25,920 shares for 6 participants in the reserved grant [8]. - The company also annulled 14,688 shares of unvested restricted stock from the 2021 incentive plan due to non-compliance with the incentive criteria [9].